Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be reconsidered, ...

February 9, 2009 — In clinical practice, there is a "hesitation" about testing for CYP2D6 before prescribing tamoxifen to reduce the risk for breast cancer recurrence, observes an editorial published ...

December 10, 2010 (San Antonio, Texas) — New analyses of data from 2 large trials have found no association between the CYP2D6 genotype and the effectiveness of tamoxifen in preventing breast cancer ...

Luminex announced that it has launched its pharmacogenetic test, the xTAG CYP2D6 Kit, which is approved by the FDA to help identify individuals who possess both common and rare CYP2D6 poor-metabolizer ...

Two studies published March 6 in the Journal of the National Cancer Institute provide insights about the CYP2D6 genotype in postmenopausal breast cancer patients and represent a major step forward in ...

The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical ...

This JCO Podcast provides observations and commentary on the JCO article “Tamoxifen pharmacogenetics and metabolism: Results from the prospective CYPTAM study” by Sanchez-Spitman et al. My name is ...

MEMPHIS, Tenn.--(BUSINESS WIRE)--While the medical community continues to debate the benefits of CYP2D6 genetic testing for women on the breast cancer treatment tamoxifen, patients using the ...

ROCHESTER, Minn. -- Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be ...

CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients is discouraged in clinical recommendations. This is based on studies with flawed methodology and should be reconsidered. The ...